相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine
Isabel Moeller et al.
ANNALS OF HEMATOLOGY (2009)
Outcome of allo-SCT for chronic myelomonocytic leukemia
S. Ocheni et al.
BONE MARROW TRANSPLANTATION (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
Azral Raza et al.
CANCER (2008)
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
P. W. Wijermans et al.
LEUKEMIA RESEARCH (2008)
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
Ahmed Aribi et al.
CANCER (2007)
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M. D. Anderson prognostic scoring system
Miloslav Beran et al.
LEUKEMIA & LYMPHOMA (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
SD Gore et al.
CANCER RESEARCH (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
H Kantarjian et al.
CANCER (2006)
An epigenetic approach to the treatment of advanced MDS;: the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
PW Wijermans et al.
ANNALS OF HEMATOLOGY (2005)
Risk assessment in chronic myelomonocytic leukemia (CMML)
U Germing et al.
LEUKEMIA & LYMPHOMA (2004)
Aberrant methylation and impaired expression of the p15INK4b cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML)
M Tessema et al.
LEUKEMIA (2003)
Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene
MK Magnusson et al.
BLOOD (2002)
Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia.: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
F Onida et al.
BLOOD (2002)
Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation
DY Zang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
